Saudi Journal of Kidney Diseases and Transplantation

BRIEF COMMUNICATIONS
Year
: 2003  |  Volume : 14  |  Issue : 4  |  Page : 492--496

The Clinical Significance of β2-microglobulin in End-Stage Renal Disease


Iqdam K Al-Taee1, Jenan J Al-Safar2, Yasine S Al-Falahi2, Ihsan A Al-Shamma3 
1 Department of Nephrology and Dialysis, Rasheed Center of Postgraduate Medical Teaching, Rasheed Hospital, Baghdad, Iraq
2 Department of Immunology, Rasheed Center of Postgraduate Medical Teaching, Rasheed Hospital, Baghdad, Iraq
3 Department of Nephrology, Rasheed Center of Postgraduate Medical Teaching, Rasheed Hospital, Baghdad, Iraq

Correspondence Address:
Iqdam K Al-Taee
Rasheed Hospital, P.O. Box 3712, Alwiya, Baghdad
Iraq

β2-microglobulin is a non glycosylated single chain protein present in light chain of HLA-class I. It is synthesized in the body and excreted in the urine. Its level increases in the blood of the chronic renal failure patients and may deposit in the soft tissue as β2-microglobulin derived amyloidosis, which appear clinically after 5 years of dialysis. We studied 64 patients (49(76%) men) with end stage renal disease (ESRD) on regular hemodialysis. The mean age was 34.3 12 years and the duration of dialysis ranged between 0.4-12 years. Twenty-five healthy persons with mean age 34 17.6 years were used as a control group. The blood level of β2-M in the control group ranged from 0.73-3.81 mg/l, while the range in the study group was 5.2-51.8 mg/l. In the urine of the control group, β2-M level ranged from 0-0.7 mg/l, while in the control group it ranged from 0.07-11.8 mg/l. There was significant difference in the β2-M level in both control and study groups. A direct correlation was found between the duration of dialysis and the level of β2-M in the blood. The traditional low flux dialyzer membrane had no effects on β2-M level in our series. We conclude that there is increased tendency with time for retention of β2-M in the ESRD patients on chronic dialysis. Using dialyzers with high flux synthetic membrane (e.g. acrylonitrile, polyamide, and polysulphone) rather than the low flux membrane may allow substantial removal of β2-M molecules, especially in patients who have little chance of receiving renal transplantation.


How to cite this article:
Al-Taee IK, Al-Safar JJ, Al-Falahi YS, Al-Shamma IA. The Clinical Significance of β2-microglobulin in End-Stage Renal Disease.Saudi J Kidney Dis Transpl 2003;14:492-496


How to cite this URL:
Al-Taee IK, Al-Safar JJ, Al-Falahi YS, Al-Shamma IA. The Clinical Significance of β2-microglobulin in End-Stage Renal Disease. Saudi J Kidney Dis Transpl [serial online] 2003 [cited 2020 Oct 23 ];14:492-496
Available from: https://www.sjkdt.org/article.asp?issn=1319-2442;year=2003;volume=14;issue=4;spage=492;epage=496;aulast=Al-Taee;type=0